Corrigendum to “Chronic hyper-leptinemia induces insulin signaling disruption in adipocytes: Implications of NOS2.” [Free Radical Biology and Medicine 112 (2017) 93–108](S0891584917306998)(10.1016/j.freeradbiomed.2017.07.016);Chronic hyper-leptinemia induces insulin signaling disruption in adipocytes: Implications of NOS2

Free Radical Biology and Medicine

Volumn 112, Issue , 2017, Pages 93-108

  Gupta, Abhishek ^a   Beg, Muheeb ^a   Kumar, Durgesh ^a,b   Shankar, Kripa ^a   Varshney, Salil ^a,b   Rajan, Sujith ^a,b   Srivastava, Ankita ^a,b   Singh, Kalpana ^c   Sonkar, Satyendra ^c   Mahdi, Abbas Ali ^c   Dikshit, Madhu ^a   Gaikwad, Anil Nilkanth ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b ACADEMY OF SCIENTIFIC AND INNOVATIVE RESEARCH ACSIR   (India)

^c KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

Adipocyte; Insulin resistance; Leptin; NOS2

Indexed keywords

AS160 PROTEIN; GLYCOGEN SYNTHASE KINASE; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; INSULIN RECEPTOR BETA; INSULIN RECEPTOR SUBSTRATE 1; LEPTIN; MAMMALIAN TARGET OF RAPAMYCIN; P70S6K PROTEIN; PROTEIN; PROTEIN KINASE B; SUPPRESSOR OF CYTOKINE SIGNALING 3; UNCLASSIFIED DRUG; GLUCOSE; NOS2 PROTEIN, HUMAN;

ADIPOCYTE; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GLUCOSE TRANSPORT; HUMAN; HYPERLEPTINEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; MITOCHONDRIAL BIOGENESIS; MOUSE; NITROSYLATION; NONHUMAN; OXIDATION REDUCTION STATE; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; 3T3-L1 CELL LINE; ADOLESCENT; ADULT; ANIMAL; C57BL MOUSE; DEFICIENCY; DRUG EFFECT; FEMALE; GENETICS; IMPLANTABLE INFUSION PUMP; KNOCKOUT MOUSE; MALE; METABOLISM; MIDDLE AGED; MITOCHONDRION; PATHOLOGY; PHOSPHORYLATION;

3T3-L1 CELLS; ADOLESCENT; ADULT; ANIMALS; FEMALE; GENE EXPRESSION; GLUCOSE; HUMANS; INFUSION PUMPS, IMPLANTABLE; INSULIN; INSULIN RESISTANCE; LEPTIN; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; MITOCHONDRIA; NITRIC OXIDE SYNTHASE TYPE II; OXYGEN CONSUMPTION; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 85025636712     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2018.05.072     Document Type: Erratum

References (81)

1. Lehr, S., Hartwig, S., Sell, H., Adipokines: a treasure trove for the discovery of biomarkers for metabolic disorders. Proteom. Clin. Appl. 6:1–2 (2012), 91–101.
2. Ohashi, K., et al. Role of anti-inflammatory adipokines in obesity-related diseases. Trends Endocrinol. Metab. 25:7 (2014), 348–355.
3. Ouchi, N., et al. Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity. Science 329:5990 (2010), 454–457.
4. Welters, I.D., et al. Circulating anti-inflammatory adipokines High Molecular Weight Adiponectin and Zinc-alpha2-glycoprotein (ZAG) are inhibited in early sepsis, but increase with clinical recovery: a pilot study. BMC Anesthesiol., 14, 2014, 124.
5. Pelleymounter, M.A., et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 269:5223 (1995), 540–543.
6. Halaas, J.L., et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269:5223 (1995), 543–546.
7. Air, E.L., et al. Insulin and leptin combine additively to reduce food intake and body weight in rats. Endocrinology 143:6 (2002), 2449–2452.
8. Shimizu, H., et al. Serum leptin concentration is associated with total body fat mass, but not abdominal fat distribution. Int. J. Obes. Relat. Metab. Disord. 21:7 (1997), 536–541.
9. Al Maskari, M.Y., Alnaqdy, A.A., Correlation between serum leptin levels, body mass index and obesity in Omanis. Sultan Qaboos Univ. Med. J. 6:2 (2006), 27–31.
10. Margetic, S., et al. Leptin: a review of its peripheral actions and interactions. Int. J. Obes. Relat. Metab. Disord. 26:11 (2002), 1407–1433.
11. Harris, R.B., Direct and indirect effects of leptin on adipocyte metabolism. Biochim. Biophys. Acta 1842:3 (2014), 414–423.
12. Siegrist-Kaiser, C.A., et al. Direct effects of leptin on brown and white adipose tissue. J. Clin. Investig. 100:11 (1997), 2858–2864.
13. Paz-Filho, G., et al. Changes in insulin sensitivity during leptin replacement therapy in leptin-deficient patients. Am. J. Physiol. Endocrinol. Metab. 295:6 (2008), E1401–E1408.
14. Sloan, C., et al. Central leptin signaling is required to normalize myocardial fatty acid oxidation rates in caloric-restricted ob/ob mice. Diabetes 60:5 (2011), 1424–1434.
15. Perez, C., et al. Leptin impairs insulin signaling in rat adipocytes. Diabetes 53:2 (2004), 347–353.
16. Artac, M., et al. Serum leptin level and waist-to-hip ratio (WHR) predict the overall survival of metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs). Breast Cancer 20:2 (2013), 174–180.
17. Ashford, A.J., Pain, V.M., Insulin stimulation of growth in diabetic rats. Synthesis and degradation of ribosomes and total tissue protein in skeletal muscle and heart. J. Biol. Chem. 261:9 (1986), 4066–4070.
18. Miao, D., Zhang, L., Leptin modulates the expression of catabolic genes in rat nucleus pulposus cells through the mitogen-activated protein kinase and Janus kinase 2/signal transducer and activator of transcription 3 pathways. Mol. Med. Rep. 12:2 (2015), 1761–1768.
19. Carvalheira, J.B., et al. Cross-talk between the insulin and leptin signaling systems in rat hypothalamus. Obes. Res. 13:1 (2005), 48–57.
20. Fruhbeck, G., Intracellular signalling pathways activated by leptin. Biochem. J. 393:Pt 1 (2006), 7–20.
21. Muller, G., et al. Leptin impairs metabolic actions of insulin in isolated rat adipocytes. J. Biol. Chem. 272:16 (1997), 10585–10593.
22. Greco, S.J., et al. Leptin inhibits glycogen synthase kinase-3beta to prevent tau phosphorylation in neuronal cells. Neurosci. Lett. 455:3 (2009), 191–194.
23. Buettner, C., et al. Leptin controls adipose tissue lipogenesis via central, STAT3-independent mechanisms. Nat. Med. 14:6 (2008), 667–675.
24. Atamer, A., et al. Evaluation of leptin and insulin resistance in patients with cholelithiasis. Indian J. Biochem. Biophys. 50:4 (2013), 266–272.
25. Atamer, A., et al. Relationship between leptin, insulin resistance, insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in patients with chronic kidney disease. J. Int. Med. Res. 36:3 (2008), 522–528.
26. Zuo, H., et al. Association between serum leptin concentrations and insulin resistance: a population-based study from China. PLoS One, 8(1), 2013, e54615.
27. Pehlivanov, B., Mitkov, M., Serum leptin levels correlate with clinical and biochemical indices of insulin resistance in women with polycystic ovary syndrome. Eur. J. Contracept. Reprod. Health Care 14:2 (2009), 153–159.
28. Shaheen, M.A., et al. Assessment of serum leptin, insulin resistance and metabolic syndrome in patients with skin tags. J. Eur. Acad. Dermatol. Venereol. 26:12 (2012), 1552–1557.
29. Hotamisligil, G.S., Shargill, N.S., Spiegelman, B.M., Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:5091 (1993), 87–91.
30. Hoehn, K.L., et al. IRS1-independent defects define major nodes of insulin resistance. Cell Metab. 7:5 (2008), 421–433.
31. Rotter, V., Nagaev, I., Smith, U., Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J. Biol. Chem. 278:46 (2003), 45777–45784.
32. Gupta, A., et al. Curcumin-3,4-dichloro phenyl pyrazole (CDPP) overcomes curcumin's low bioavailability, inhibits adipogenesis and ameliorates dyslipidemia by activating reverse cholesterol transport. Metab.: Clin. Exp. 73 (2017), 109–124.
33. Beg, M., et al. PPP2R5B, a regulatory subunit of PP2A, contributes to adipocyte insulin resistance. Mol. Cell Endocrinol. 437 (2016), 97–107.
34. Shankar, K., et al. Cucumis melo ssp. Agrestis var. Agrestis ameliorates high fat diet induced Dyslipidemia in Syrian golden hamsters and inhibits adipogenesis in 3T3-L1 adipocytes. Pharmacogn. Mag. 11:Suppl 4 (2015), S501–S510.
35. Rajan, S., et al. Chronic hyperinsulinemia reduces insulin sensitivity and metabolic functions of brown adipocyte. J. Endocrinol., 2016.
36. Duplain, H., et al. Stimulation of peroxynitrite catalysis improves insulin sensitivity in high fat diet-fed mice. J. Physiol. 586:16 (2008), 4011–4016.
37. Srikanthan, P., Karlamangla, A.S., Relative muscle mass is inversely associated with insulin resistance and prediabetes. Findings from the third National Health and Nutrition Examination Survey. J. Clin. Endocrinol. Metab. 96:9 (2011), 2898–2903.
38. Mohammad, A. Kopeisy, Haitham, A. Azeem, Salwa, I. Wasfy, Evaluation of leptin levels in serum of patients with non insulin dependant diabetic nephropathy. Anveshana Ayurveda Med. J., 9(3), 2011.
39. Al-Sultan, A.I., Al-Elq, A.H., Leptin levels in normal weight and obese saudi adults. J. Fam. Community Med. 13:3 (2006), 97–102.
40. Bouloumie, A., et al. Leptin induces oxidative stress in human endothelial cells. FASEB J. 13:10 (1999), 1231–1238.
41. Hoehn, K.L., et al. Insulin resistance is a cellular antioxidant defense mechanism. Proc. Natl. Acad. Sci. USA 106:42 (2009), 17787–17792.
42. Sansbury, B.E., Hill, B.G., Regulation of obesity and insulin resistance by nitric oxide. Free Radic. Biol. Med. 73 (2014), 383–399.
43. Yasukawa, T., et al. S-nitrosylation-dependent inactivation of Akt/protein kinase B in insulin resistance. J. Biol. Chem. 280:9 (2005), 7511–7518.
44. Bosch, R.R., et al. Regulation of GLUT1-mediated glucose uptake by PKClambda-PKCbeta(II) interactions in 3T3-L1 adipocytes. Biochem. J. 384:Pt 2 (2004), 349–355.
45. Harmon, A.W., Paul, D.S., Patel, Y.M., MEK inhibitors impair insulin-stimulated glucose uptake in 3T3-L1 adipocytes. Am. J. Physiol. Endocrinol. Metab. 287:4 (2004), E758–E766.
46. Gomez-Ambrosi, J., et al. Reduced adipose tissue mass and hypoleptinemia in iNOS deficient mice: effect of LPS on plasma leptin and adiponectin concentrations. FEBS Lett. 577:3 (2004), 351–356.
47. Zeigerer, A., et al. Insulin regulates leptin secretion from 3T3-L1 adipocytes by a PI 3 kinase independent mechanism. Exp. Cell Res. 314:11–12 (2008), 2249–2256.
48. Koopmans, S.J., et al. Effect of hyperinsulinemia on plasma leptin concentrations and food intake in rats. Am. J. Physiol. 274:6 Pt 1 (1998), E998–E1001.
49. Osegbe, I., Okpara, H., Azinge, E., Relationship between serum leptin and insulin resistance among obese Nigerian women. Ann. Afr. Med. 15:1 (2016), 14–19.
50. Langendonk, J.G., et al. Circadian rhythm of plasma leptin levels in upper and lower body obese women: influence of body fat distribution and weight loss. J. Clin. Endocrinol. Metab. 83:5 (1998), 1706–1712.
51. Nowak, C., et al. Protein biomarkers for insulin resistance and type 2 diabetes risk in two large community cohorts. Diabetes 65:1 (2016), 276–284.
52. Hilton, L.K., Loucks, A.B., Low energy availability, not exercise stress, suppresses the diurnal rhythm of leptin in healthy young women. Am. J. Physiol. Endocrinol. Metab. 278:1 (2000), E43–E49.
53. Boden, G., et al. Effects of prolonged hyperinsulinemia on serum leptin in normal human subjects. J. Clin. Investig. 100:5 (1997), 1107–1113.
54. Ceddia, R.B., et al. Leptin inhibits insulin-stimulated incorporation of glucose into lipids and stimulates glucose decarboxylation in isolated rat adipocytes. J. Endocrinol. 158:3 (1998), R7–R9.
55. Ceddia, R.B., et al. Leptin stimulates uncoupling protein-2 mRNA expression and Krebs cycle activity and inhibits lipid synthesis in isolated rat white adipocytes. Eur. J. Biochem. 267:19 (2000), 5952–5958.
56. Baruah, M.P., Kalra, S., Ranabir, S., Metformin; A character actor in the leptin story!. Indian J. Endocrinol. Metab. 16:Suppl 3 (2012), S532–S533.
57. Kuroda, M., et al. DNA methylation suppresses leptin gene in 3T3-L1 adipocytes. PLoS One, 11(8), 2016, e0160532.
58. Zhou, L., et al. Serum leptin level is associated with glycaemic control in newly diagnosed type 2 diabetes patients: a 1-year cohort study. Diabetes Metab., 2016.
59. Yu, X., et al. Egr-1 decreases adipocyte insulin sensitivity by tilting PI3K/Akt and MAPK signal balance in mice. EMBO J. 30:18 (2011), 3754–3765.
60. Navarro, R., et al. Superoxide anions are involved in doxorubicin-induced ERK activation in hepatocyte cultures. Ann. N. Y. Acad. Sci. 1090 (2006), 419–428.
61. Yu, H., et al. Dissociation of mitogen-activated protein kinase activation from the oxidative burst in differentiated HL-60 cells and human neutrophils. J. Biol. Chem. 270:26 (1995), 15719–15724.
62. Kim, J.A., Wei, Y., Sowers, J.R., Role of mitochondrial dysfunction in insulin resistance. Circ. Res. 102:4 (2008), 401–414.
63. Zamora, M., Villena, J.A., Targeting mitochondrial biogenesis to treat insulin resistance. Curr. Pharm. Des. 20:35 (2014), 5527–5557.
64. Soskic, S.S., et al. Regulation of inducible nitric oxide synthase (iNOS) and its potential role in insulin resistance, diabetes and heart failure. Open Cardiovasc. Med. J. 5 (2011), 153–163.
65. Elizalde, M., et al. Expression of nitric oxide synthases in subcutaneous adipose tissue of nonobese and obese humans. J. Lipid Res. 41:8 (2000), 1244–1251.
66. de Vera, M.E., et al. Transcriptional regulation of human inducible nitric oxide synthase (NOS2) gene by cytokines: initial analysis of the human NOS2 promoter. Proc. Natl. Acad. Sci. USA 93:3 (1996), 1054–1059.
67. Hiroi, M., et al. Anti-inflammatory cytokine interleukin-4 inhibits inducible nitric oxide synthase gene expression in the mouse macrophage cell line RAW264.7 through the repression of octamer-dependent transcription. Mediat. Inflamm., 2013, 2013, 369693.
68. Otero, M., Gomez Reino, J.J., Gualillo, O., Synergistic induction of nitric oxide synthase type II: in vitro effect of leptin and interferon-gamma in human chondrocytes and ATDC5 chondrogenic cells. Arthritis Rheum. 48:2 (2003), 404–409.
69. Otero, M., et al. Signalling pathway involved in nitric oxide synthase type II activation in chondrocytes: synergistic effect of leptin with interleukin-1. Arthritis Res. Ther. 7:3 (2005), R581–R591.
70. Raso, G.M., et al. Leptin potentiates IFN-gamma-induced expression of nitric oxide synthase and cyclo-oxygenase-2 in murine macrophage J774A.1. Br. J. Pharmacol. 137:6 (2002), 799–804.
71. Perreault, M., Marette, A., Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat. Med. 7:10 (2001), 1138–1143.
72. Haddad, Y., Couture, R., Interplay between the kinin B1 receptor and inducible nitric oxide synthase in insulin resistance. Br. J. Pharmacol. 173:12 (2016), 1988–2000.
73. Fink, T., Zachar, V., Adipogenic differentiation of human mesenchymal stem cells. Methods Mol. Biol. 698 (2011), 243–251.
74. Heymsfield, S.B., et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. J. Am. Med. Assoc. 282:16 (1999), 1568–1575.
75. Ravussin, Y., et al. Effects of chronic leptin infusion on subsequent body weight and composition in mice: can body weight set point be reset?. Mol. Metab. 3:4 (2014), 432–440.
76. Mittendorfer, B., et al. Recombinant human leptin treatment does not improve insulin action in obese subjects with type 2 diabetes. Diabetes 60:5 (2011), 1474–1477.
77. Benomar, Y., et al. In vivo leptin infusion impairs insulin and leptin signalling in liver and hypothalamus. Mol. Cell Endocrinol. 242:1–2 (2005), 59–66.
78. Singh, M.K., et al. High-fat diet and leptin treatment alter skeletal muscle insulin-stimulated phosphatidylinositol 3-kinase activity and glucose transport. Metabolism 52:9 (2003), 1196–1205.
79. Kwon, H., Pessin, J.E., Adipokines mediate inflammation and insulin resistance. Front. Endocrinol., 4, 2013, 71.
80. Deng, T., et al. Class II major histocompatibility complex plays an essential role in obesity-induced adipose inflammation. Cell Metab. 17:3 (2013), 411–422.
81. Merial, C., et al. Nitric oxide-dependent downregulation of adipocyte UCP-2 expression by tumor necrosis factor-alpha. Am. J. Physiol. Cell Physiol. 279:4 (2000), C1100–C1106.